{"id":55819,"date":"2026-01-29T21:22:11","date_gmt":"2026-01-29T13:22:11","guid":{"rendered":"https:\/\/flcube.com\/?p=55819"},"modified":"2026-01-29T21:22:12","modified_gmt":"2026-01-29T13:22:12","slug":"lisata-reclaims-certepetide-china-rights-amid-kuva-acquisition-cvr-milestone-triggered","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55819","title":{"rendered":"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered"},"content":{"rendered":"\n<p><strong>Lisata Therapeutics<\/strong> announced the termination of its licensing agreement with <strong>Qilu Pharmaceutical Co., Ltd.<\/strong> for <strong>certepetide<\/strong> (formerly CEND\u20111) in Greater China, triggering the return of all development and commercialization rights. The termination follows <strong>Lisata\u2019s acquisition by Kuva Labs<\/strong> for <strong>$4.00 per share<\/strong>, which established two milestone\u2011based Contingent Value Rights (CVRs) for shareholders.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-terms\">Deal Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Original Agreement<\/strong><\/td><td>2021 licensing deal granting Qilu exclusive Greater China rights for certepetide<\/td><\/tr><tr><td><strong>Terminating Party<\/strong><\/td><td>Lisata Therapeutics<\/td><\/tr><tr><td><strong>Acquirer<\/strong><\/td><td>Kuva Labs (US\u2011based)<\/td><\/tr><tr><td><strong>Acquisition Price<\/strong><\/td><td>USD\u202f4.00 per share in cash<\/td><\/tr><tr><td><strong>CVR \u2460<\/strong><\/td><td>USD\u202f1.00 per share upon return of Greater China rights within 12\u202fmonths (now triggered)<\/td><\/tr><tr><td><strong>CVR \u2461<\/strong><\/td><td>USD\u202f1.00 per share upon Kuva filing NDA for certepetide in any region<\/td><\/tr><tr><td><strong>Total Potential Premium<\/strong><\/td><td>~180% for shareholders<\/td><\/tr><tr><td><strong>Post\u2011Acquisition Rights<\/strong><\/td><td>Global certepetide rights transfer to Kuva Labs<\/td><\/tr><tr><td><strong>Qilu Obligation<\/strong><\/td><td>Complete ongoing Phase\u202fII study in metastatic pancreatic ductal adenocarcinoma<\/td><\/tr><tr><td><strong>Data Rights<\/strong><\/td><td>Lisata\/Kuva may consult on using generated trial data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-technology-platform\">Drug Profile &amp; Technology Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Internalizing RGD cyclic peptide analog<\/strong> that specifically targets tumors and exhibits penetration activity while modulating the <strong>tumor immune microenvironment (TIME)<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Potential:<\/strong> Anti\u2011tumor activity, tumor diagnosis applications, and drug conjugate development<\/li>\n\n\n\n<li><strong>Kuva\u2019s IPR Strategy:<\/strong> Plans to combine certepetide with its proprietary <strong>NanoMark platform<\/strong> to develop next\u2011generation MRI contrast agents for solid tumors<\/li>\n\n\n\n<li><strong>ADC Integration:<\/strong> Lisata previously licensed certepetide to <strong>Catalent<\/strong> for integration into the <strong>SMARTag Antibody\u2011Drug Conjugate (ADC)<\/strong> platform as a non\u2011cytotoxic payload<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> First\u2011in\u2011class tumor\u2011penetrating peptide with dual diagnostic and therapeutic applications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-implications\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pancreatic Cancer Market:<\/strong> Global metastatic pancreatic ductal adenocarcinoma market valued at <strong>$2.5\u202fbillion<\/strong>, with limited effective therapies<\/li>\n\n\n\n<li><strong>CVR Value Creation:<\/strong> First milestone triggered adds <strong>$1.00 per share<\/strong> immediate value; second CVR contingent on NDA filing creates <strong>additional upside<\/strong><\/li>\n\n\n\n<li><strong>Greater China Opportunity:<\/strong> Return of rights allows Kuva to pursue direct partnerships or new licensing deals in <strong>\u00a550\u202fbillion+<\/strong> China oncology market<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Certepetide\u2019s versatility across imaging, ADCs, and direct therapy positions it as a <strong>pipeline\u2011in\u2011a\u2011molecule<\/strong> asset<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Kuva to integrate certepetide into NanoMark development pipeline; Catalent ADC program continues in parallel; Qilu to complete Phase\u202fII study by <strong>H2\u202f2027<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding CVR payouts, clinical trial outcomes, and strategic value realization for certepetide. Actual results may differ due to clinical trial risks, NDA filing timelines, and partnership negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55823,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4580,208],"class_list":["post-55819","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-lisata-therapeutics","tag-qilu-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for certepetide (formerly CEND\u20111) in Greater China, triggering the return of all development and commercialization rights. The termination follows Lisata\u2019s acquisition by Kuva Labs for $4.00 per share, which established two milestone\u2011based Contingent Value Rights (CVRs) for shareholders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55819\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered\" \/>\n<meta property=\"og:description\" content=\"Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for certepetide (formerly CEND\u20111) in Greater China, triggering the return of all development and commercialization rights. The termination follows Lisata\u2019s acquisition by Kuva Labs for $4.00 per share, which established two milestone\u2011based Contingent Value Rights (CVRs) for shareholders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55819\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T13:22:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-29T13:22:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2909.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55819#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55819\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered\",\"datePublished\":\"2026-01-29T13:22:11+00:00\",\"dateModified\":\"2026-01-29T13:22:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55819\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55819#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2909.webp\",\"keywords\":[\"Lisata Therapeutics\",\"Qilu Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55819#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55819\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55819\",\"name\":\"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55819#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55819#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2909.webp\",\"datePublished\":\"2026-01-29T13:22:11+00:00\",\"dateModified\":\"2026-01-29T13:22:12+00:00\",\"description\":\"Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for certepetide (formerly CEND\u20111) in Greater China, triggering the return of all development and commercialization rights. The termination follows Lisata\u2019s acquisition by Kuva Labs for $4.00 per share, which established two milestone\u2011based Contingent Value Rights (CVRs) for shareholders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55819#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55819\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55819#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2909.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2909.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55819#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered - Insight, China&#039;s Pharmaceutical Industry","description":"Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for certepetide (formerly CEND\u20111) in Greater China, triggering the return of all development and commercialization rights. The termination follows Lisata\u2019s acquisition by Kuva Labs for $4.00 per share, which established two milestone\u2011based Contingent Value Rights (CVRs) for shareholders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55819","og_locale":"en_US","og_type":"article","og_title":"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered","og_description":"Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for certepetide (formerly CEND\u20111) in Greater China, triggering the return of all development and commercialization rights. The termination follows Lisata\u2019s acquisition by Kuva Labs for $4.00 per share, which established two milestone\u2011based Contingent Value Rights (CVRs) for shareholders.","og_url":"https:\/\/flcube.com\/?p=55819","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-29T13:22:11+00:00","article_modified_time":"2026-01-29T13:22:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2909.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55819#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55819"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered","datePublished":"2026-01-29T13:22:11+00:00","dateModified":"2026-01-29T13:22:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55819"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55819#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2909.webp","keywords":["Lisata Therapeutics","Qilu Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55819#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55819","url":"https:\/\/flcube.com\/?p=55819","name":"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55819#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55819#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2909.webp","datePublished":"2026-01-29T13:22:11+00:00","dateModified":"2026-01-29T13:22:12+00:00","description":"Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for certepetide (formerly CEND\u20111) in Greater China, triggering the return of all development and commercialization rights. The termination follows Lisata\u2019s acquisition by Kuva Labs for $4.00 per share, which established two milestone\u2011based Contingent Value Rights (CVRs) for shareholders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55819#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55819"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55819#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2909.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2909.webp","width":1080,"height":608,"caption":"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55819#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2909.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55819"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55819\/revisions"}],"predecessor-version":[{"id":55824,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55819\/revisions\/55824"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55823"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}